Phathom Total Assets from 2010 to 2024

PHAT Stock

USD 8.97 0.12 1.32%

Phathom Pharmaceuticals Total Assets yearly trend continues to be comparatively stable with very little volatility. Total Assets will likely drop to about 242.2 M in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2018-09-30

Previous Quarter

319.4 M

Current Value

387 M

Quarterly Volatility

106.6 M

Covid

Check Phathom Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Phathom Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 8.3 M, Depreciation And Amortization of 603.8 K or Interest Expense of 44.1 M, as well as many indicators such as Price To Sales Ratio of 549, Dividend Yield of 0.0 or Days Sales Outstanding of 701. Phathom financial statements analysis is a perfect complement when working with Phathom Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Phathom Pharmaceuticals Correlation against competitors.

For more information on how to buy Phathom Stock please use our How to Invest in Phathom Pharmaceuticals guide.

Latest Phathom Pharmaceuticals' Total Assets Growth Pattern

Below is the plot of the Total Assets of Phathom Pharmaceuticals over the last few years. Total assets refers to the total amount of Phathom Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Phathom Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Phathom Pharmaceuticals' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Phathom Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 413.84 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Phathom Total Assets Regression Statistics

	Arithmetic Mean	104,714,904
	Geometric Mean	8,540,935
	Coefficient Of Variation	135.47
	Mean Deviation	124,575,485
	Median	902,000
	Standard Deviation	141,862,338
	Sample Variance	20124.9T
	Range	412.9M
	R-Value	0.80
	Mean Square Error	7684.1T
	R-Squared	0.65
	Significance	0.0003
	Slope	25,484,986
	Total Sum of Squares	281748.9T

Phathom Total Assets History

	2024	242.2 M
	2023	413.8 M
	2022	164.8 M
	2021	189.4 M
	2020	295.1 M
	2019	257.2 M

Other Fundumenentals of Phathom Pharmaceuticals

Intangibles To Total Assets

Phathom Pharmaceuticals Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Capital Surpluse	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Net Working Capital	Short Term Debt	Long Term Debt	Long Term Debt Total	Common Stock	Property Plant Equipment	Net Receivables
Total Assets		0.25	0.26	0.86	-0.95	-0.87	0.84	0.94	0.77	0.74	0.94	1.0	1.0	0.07	0.77	0.72	0.85	0.71	0.62
Total Stockholder Equity	0.25		1.0	-0.03	-0.36	0.18	0.09	0.22	-0.38	0.8	0.31	0.26	0.27	0.43	-0.35	-0.27	-0.25	-0.18	-0.41
Net Tangible Assets	0.26	1.0		-0.02	-0.38	0.17	0.1	0.23	-0.36	0.81	0.32	0.28	0.29	0.42	-0.34	-0.26	-0.24	-0.17	-0.39
Current Deferred Revenue	0.86	-0.03	-0.02		-0.78	-0.96	0.9	0.93	0.85	0.55	0.87	0.86	0.84	0.1	0.88	0.87	0.87	0.7	0.59
Net Debt	-0.95	-0.36	-0.38	-0.78		0.78	-0.77	-0.85	-0.72	-0.81	-0.84	-0.96	-0.96	-0.14	-0.6	-0.52	-0.73	-0.63	-0.63
Retained Earnings	-0.87	0.18	0.17	-0.96	0.78		-0.8	-0.9	-0.94	-0.44	-0.84	-0.86	-0.86	0.14	-0.94	-0.89	-0.91	-0.72	-0.73
Accounts Payable	0.84	0.09	0.1	0.9	-0.77	-0.8		0.84	0.7	0.54	0.8	0.83	0.79	0.46	0.72	0.7	0.81	0.86	0.47
Capital Surpluse	0.94	0.22	0.23	0.93	-0.85	-0.9	0.84		0.72	0.73	0.99	0.94	0.93	0.05	0.82	0.83	0.8	0.66	0.45
Total Liab	0.77	-0.38	-0.36	0.85	-0.72	-0.94	0.7	0.72		0.24	0.64	0.76	0.75	-0.21	0.88	0.76	0.91	0.72	0.91
Net Invested Capital	0.74	0.8	0.81	0.55	-0.81	-0.44	0.54	0.73	0.24		0.76	0.75	0.75	0.29	0.24	0.27	0.32	0.22	0.11
Short Long Term Debt	0.94	0.31	0.32	0.87	-0.84	-0.84	0.8	0.99	0.64	0.76		0.94	0.94	0.05	0.76	0.79	0.75	0.63	0.37
Total Current Assets	1.0	0.26	0.28	0.86	-0.96	-0.86	0.83	0.94	0.76	0.75	0.94		1.0	0.08	0.76	0.72	0.85	0.71	0.61
Net Working Capital	1.0	0.27	0.29	0.84	-0.96	-0.86	0.79	0.93	0.75	0.75	0.94	1.0		0.02	0.75	0.71	0.83	0.67	0.61
Short Term Debt	0.07	0.43	0.42	0.1	-0.14	0.14	0.46	0.05	-0.21	0.29	0.05	0.08	0.02		-0.24	-0.19	-0.05	0.29	-0.27
Long Term Debt	0.77	-0.35	-0.34	0.88	-0.6	-0.94	0.72	0.82	0.88	0.24	0.76	0.76	0.75	-0.24		0.97	0.94	0.67	0.68
Long Term Debt Total	0.72	-0.27	-0.26	0.87	-0.52	-0.89	0.7	0.83	0.76	0.27	0.79	0.72	0.71	-0.19	0.97		0.87	0.61	0.49
Common Stock	0.85	-0.25	-0.24	0.87	-0.73	-0.91	0.81	0.8	0.91	0.32	0.75	0.85	0.83	-0.05	0.94	0.87		0.78	0.79
Property Plant Equipment	0.71	-0.18	-0.17	0.7	-0.63	-0.72	0.86	0.66	0.72	0.22	0.63	0.71	0.67	0.29	0.67	0.61	0.78		0.55
Net Receivables	0.62	-0.41	-0.39	0.59	-0.63	-0.73	0.47	0.45	0.91	0.11	0.37	0.61	0.61	-0.27	0.68	0.49	0.79	0.55

Click cells to compare fundamentals

About Phathom Pharmaceuticals Financial Statements

Phathom Pharmaceuticals shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Phathom Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Phathom Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Phathom Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Total Assets	413.8 M	242.2 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Phathom Stock Analysis

When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC